Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gain Therapeutics Inc
(NQ:
GANX
)
3.180
+0.030 (+0.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
71,353
Open
3.110
Bid (Size)
2.500 (4)
Ask (Size)
3.990 (50)
Prev. Close
3.150
Today's Range
3.000 - 3.260
52wk Range
2.000 - 6.190
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
April 08, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
April 02, 2024
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Performance
YTD
-12.28%
-12.28%
1 Month
-25.35%
-25.35%
3 Month
-4.50%
-4.50%
6 Month
+4.95%
+4.95%
1 Year
-36.40%
-36.40%
More News
Read More
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
April 01, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023
March 26, 2024
Via
InvestorPlace
Gain Therapeutics: Q4 Earnings Insights
March 26, 2024
Via
Benzinga
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
March 26, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Present at Public Ventures Discovery Day
March 15, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
March 05, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: Gain Therapeutics Highlights Lead Program Data Showcasing Its Impact On Cellular Death For Treating Parkinson's Disease
March 05, 2024
Via
Benzinga
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
February 27, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
February 14, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
February 06, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
January 31, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 16, 2024
Via
Benzinga
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
January 02, 2024
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
December 04, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
December 01, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
November 29, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
November 24, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 21, 2023
Via
Benzinga
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
November 21, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
November 20, 2023
Via
Benzinga
Gain Therapeutics Announces Proposed Public Offering
November 20, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
Gain Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.